
The latest announcement is out from ANI Pharmaceuticals ( ($ANIP) ). On November 16, 2026, ANI Pharmaceuticals published an updated investor presentation on its investor-relations website. The presentation covered the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals | 69.13 | -6.82 | -8.98% |
| Name | Price | % Change | |
|---|---|---|---|
| $69.13 | -8.98% |

The latest announcement is out from ANI Pharmaceuticals ( ($ANIP) ). On November 16, 2026, ANI Pharmaceuticals published an updated investor presentation on its investor-relations website. The presentation covered the

Ani Pharmaceuticals (($ANIP)) has held its Q3 earnings call. Read on for the main highlights of the call. Ani Pharmaceuticals’ Earnings Call Signals Growth Despite Cortrophin Setback The earnings call

Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $121 from $119 and keeps a Buy rating on the shares. Published first on TheFly –

ANI Pharmaceuticals ( ($ANIP) ) has issued an update. On November 4, 2026, ANI Pharmaceuticals entered into a 364-day senior bridge credit facility with lenders and JPMorgan Chase Bank as

Reports Q3 revenue $290.8M, consensus $280.2M. “In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company,” said Nikhil Lalwani, President and

FY26 consensus $9.26. Narrows FY26 revenue to $1.085B-$1.125B from $1.08B-$1.14B, consensus $1.1B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s

ANI Pharmaceuticals ( ($ANIP) ) has shared an announcement. On November 5, 2026, ANI Pharmaceuticals reported third-quarter revenue of $290.8 million, up 27.6% year over year, with GAAP net income

ANI Pharmaceuticals (ANIP) announced a recommended public offer to acquire Egetis Therapeutics. Egetis is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases

ANI Pharmaceuticals (ANIP) announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug, or RLD,

ANI Pharmaceuticals (ANIP) announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 26, 2027TBA | $1.62B | $2.58 | $303.61M | -0.05 | 13.80 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.